ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,681.59
      1.37%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lexicon Pharmaceuticals Inc (LXRX)

      7. Lexicon Pharmaceuticals Inc (LXRX) News

      LXRX

      Lexicon Pharmaceuticals (LXRX)

      Lexicon Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:LXRX
      DateTimeSourceHeadlineSymbolCompany
      11/07/20167:00AMPR Newswire (US)Lexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristo...NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/01/20168:42AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/01/20167:00AMPR Newswire (US)Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Third Quarter Financial ResultsNASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/31/20164:30PMPR Newswire (US)Lexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical OncologyNASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/25/20166:58AMPR Newswire (US)Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/25/20166:00AMPR Newswire (US)Lexicon To Report Third Quarter 2016 Financial Results On November 1, 2016NASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/05/20169:24AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/05/20167:00AMPR Newswire (US)Lexicon Pharmaceuticals Announces Agreement To Buy Out Remaining Obligations To Symphony IconNASDAQ:LXRXLexicon Pharmaceuticals Inc
      10/03/20167:00AMPR Newswire (US)Telecast Data Presented At The 2016 North American Neuroendocrine Tumor Society Annual SymposiumNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/14/20165:46PMPR Newswire (US)FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid SyndromeNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/09/20166:58AMPR Newswire (US)Lexicon Reports Positive Top-Line Results In Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/07/20164:01PMPR Newswire (US)Lexicon To Present At The Bank Of America Merrill Lynch Global Health Care ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/12/20168:00AMPR Newswire (US)Lexicon To Present At The 2016 Wedbush PacGrow Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/04/20164:12PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/04/20168:55AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/04/20167:00AMPR Newswire (US)Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Second Quarter Financial ResultsNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/01/20164:01PMPR Newswire (US)Lexicon To Report Second Quarter 2016 Financial Results On August 4, 2016NASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/18/20164:01PMPR Newswire (US)Lexicon Announces The Validation By The European Medicine Agency Of The Marketing Authorization Application For Telotristat E...NASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/07/20164:01PMPR Newswire (US)Lexicon To Present At The Cantor Fitzgerald Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/22/201610:00AMGlobeNewswire Inc.Frank Palantoni joins Laboratoire M2 as CEONASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/20/201610:37AMEdgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/14/20164:48PMEdgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/08/20168:23AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/06/20164:01PMPR Newswire (US)Lexicon To Present At The Jefferies 2016 Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/02/20164:15PMPR Newswire (US)Lexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education To Patients, Caregivers An...NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/31/20168:00AMPR Newswire (US)Lexicon Announces FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrom...NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/23/20165:57PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/16/20165:24PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/16/20165:22PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      05/10/20168:00AMPR Newswire (US)Praveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And DevelopmentNASDAQ:LXRXLexicon Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:LXRX